Results 171 to 180 of about 76,116 (300)

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Retraction Note to: FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1–TYMS axis uncoupling in 5-FU resistance

Cell Death and Disease, 2021
Kitti Intuyod, Paula Saavedra-García, Stefania Zona, Chun-Fui Lai, Yannasittha Jiramongkol, Kulthida Vaeteewoottacharn, Chawalit Pairojkul, Shang Yao, Jay-Sze Yong, Sasanan Trakansuebkul, Sakda Waraasawapati, Vor Luvira, Sopit Wongkham, Somchai Pinlaor, Eric W.-F. Lam   +14 more
doaj   +1 more source

Immune Microenvironmental Analysis of Intraductal Papillary Neoplasms of the Bile Duct in Occupational Cholangiocarcinoma: Associations with Tumor Size. [PDF]

Cancers (Basel)
Kinoshita M, Kubo S, Kato K, Inoue D, Yasuda T, Hatta K, Sugimoto A, Tanaka R, Tauchi J, Nishimura S, Watanabe G, Nishio K, Shinkawa H, Ishizawa T, Sato Y.   +14 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

The coefficient of variation of CT values for predicting lymph node metastasis in extrahepatic cholangiocarcinoma. [PDF]

PLoS One
Chiba N, Abe Y, Kojima H, Suda R, Nakagawa M, Ochiai S, Gunji T, Sano T, Tabuchi S, Ishizaki T, Kawachi S.   +10 more
europepmc   +1 more source

Real‐World Safety and Efficacy of Pola‐R‐CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients

Cancer Science, EarlyView.
In this analysis of a diverse cohort of 500 patients with previously untreated DLBCL in a real‐world clinical setting, Pola‐R‐CHP demonstrated high response rates at end‐of‐treatment, which were consistent among the overall population, in patients > 80 years and regardless of International Prognostic Index status and cell of origin subtypes.
Takahiro Kumode, Hitomi Sawa, Kohta Miyawaki, Atsushi Satake, Nobuhiro Kanemura, Ritsuro Suzuki, Yuki Fujiwara, Yasuhiro Nagate, Shuichi Ota, Takahiro Fujino, Hideki Goto, Noriko Fukuhara, Mamiko Sakata‐Yanagimoto, Koji Izutsu, Momoko Nishikori, Hirohiko Shibayama, Daisuke Ennishi, Takayuki Shimose, Mai Asai, Itaru Matsumura, Koichi Akashi, Koji Kato   +21 more
wiley   +1 more source

Distal cholangiocarcinoma arising in a Choi Type I septate common bile duct: a case report. [PDF]

J Surg Case Rep
Thorat S, Baviskar M, Toradmal D, Kuldipak A, Gaikwad N, Gavhane N.   +5 more
europepmc   +1 more source

Liver: Cholangiocarcinoma

, 1900
Cholangiocarcinoma. COMMENT: Diffuse involvement by tumor (Green = ""normal"" liver)--small areas of infarct also present ...
MUSC Department of Pathology and Laboratory Medicine
core  

LAMC2+ Epithelial Cells Drive Bladder Cancer Progression and Predict Immunotherapy Response via SERPINB3/STAT3/CD44 Axis

Cancer Science, EarlyView.
This study identified LAMC2+ epithelial cells through single‐cell sequencing and found that high expression of LAMC2 is associated with the malignant progression of bladder cancer. HdWGCNA and transcriptome sequencing revealed the SerpinB3/STAT3/CD44 axis. Diosmetin was selected as a potential LAMC2 inhibitor.
Yutong Chen, Yunzhong Jiang, Zezhong Yang, Minxuan Jing, Wentai Wu, Jiale He, Lu Wang, Minghai Ma, Yaodong Zhang, Min Wang, Jianpeng Li, Yuanchun Pu, Bingliang He, Yanjia Liu, Kaibo Mi, Hang Liu, Mengzhao Zhang, Jinhai Fan   +17 more
wiley   +1 more source

Correction: MCL-1 as a tumor microenvironment-linked survival node in cholangiocarcinoma. [PDF]

Front Oncol
Hashida H, Kobayashi A, Akagami M, Okamoto T, Tanaka H.   +4 more
europepmc   +1 more source